Insider Transactions in Q2 2025 at Iovance Biotherapeutics, Inc. (IOVA)
Insider Transaction List (Q2 2025)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 05
2025
|
Daniel Gordon Kirby Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$30,000
$1.84 P/Share
|
Jun 02
2025
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
22,127
-5.19%
|
$22,127
$1.76 P/Share
|
Jun 02
2025
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
52,085
+10.88%
|
-
|
Jun 02
2025
|
Raj K. Puri Chief Regulatory Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,467
-1.16%
|
$2,467
$1.76 P/Share
|
Jun 02
2025
|
Raj K. Puri Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,469
+2.51%
|
-
|
Jun 02
2025
|
Jean Marc Bellemin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,464
-6.87%
|
$4,464
$1.76 P/Share
|
Jun 02
2025
|
Jean Marc Bellemin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,789
+11.91%
|
-
|
Jun 02
2025
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,250
-6.26%
|
$6,250
$1.76 P/Share
|
Jun 02
2025
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,305
+10.97%
|
-
|
Jun 02
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,448
-6.11%
|
$6,448
$1.76 P/Share
|
Jun 02
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,695
+10.73%
|
-
|
May 23
2025
|
Raj K. Puri Chief Regulatory Officer |
BUY
Open market or private purchase
|
Direct |
5,600
+2.64%
|
$5,600
$1.74 P/Share
|
May 14
2025
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Open market or private purchase
|
Direct |
25,000
+6.26%
|
$25,000
$1.69 P/Share
|